Bristol‑Myers Squibb and Oxford BioTherapeutics announced a multi‑year collaboration to discover and develop next‑generation T‑cell engager therapies for solid tumors. The partnership leverages OBT’s OGAP®‑Verify platform, which identifies tumor‑selective membrane proteins, and BMY’s expertise in translating oncology innovations into clinical and commercial success.
Under the agreement, OBT will identify tumor‑selective targets and design development candidates, while BMY will advance those candidates through preclinical development and beyond. OBT will receive upfront research funding, and the deal includes potential milestone payments and royalties on any products that reach commercialization, although specific financial terms were not disclosed.
The collaboration validates OBT’s platform and follows two prior major pharma partnerships in 2025 with GSK and Roche. OBT’s third partnership in 12 months underscores the growing confidence in its technology and its ability to generate development‑ready candidates for large pharmaceutical companies.
For BMY, the alliance expands its oncology pipeline into the bispecific T‑cell engager space, complementing its existing growth assets such as Opdivo, Breyanzi, and emerging radiopharmaceuticals. The partnership is positioned to accelerate the delivery of innovative solid‑tumor therapies and strengthen BMY’s competitive position in oncology.
"We made significant progress in 2025, with real momentum in our Growth Portfolio and a strengthened balance sheet that provides the strategic flexibility to continue investing in growth drivers," said Christopher Boerner, Ph.D., CEO of Bristol‑Myers Squibb. "2026 is data‑rich, and we are advancing a truly differentiated pipeline with multiple pivotal readouts expected in the back half of the year." Christian Rohlff, CEO of Oxford BioTherapeutics, added, "Collaborating with Bristol‑Myers Squibb, a global leader in oncology, represents an important milestone for OBT and underscores the momentum behind our partnerships with leading pharmaceutical companies. This new partnership builds on the proven strength of our platform to identify and validate highly differentiated, tumour‑selective targets and reflects the growing confidence in our ability to translate that science into development‑ready therapeutic candidates."
Bristol‑Myers Squibb’s strong Q4 2025 earnings—$12.5 billion in revenue and $1.26 in adjusted EPS—provided a solid financial backdrop for the collaboration. The company’s 2026 outlook, projecting $46 billion to $47.5 billion in revenue and $6.05 to $6.35 in non‑GAAP EPS, signals confidence in its growth portfolio and the added value of new partnerships such as this one. The collaboration is expected to reinforce BMY’s leadership in oncology and support its strategy of expanding into innovative modalities like T‑cell engagers.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.